Peramivir. A new and potent neuraminidase inhibitor for the treatment of influenza;Peramivir: Un nuevo y potente inhibidor de la neuraminidasa para el tratamiento de las infecciones gripales

Revista Espanola de Quimioterapia

Volumn 19, Issue 4, 2006, Pages 317-322

  Reina, Jordi ^a  

^a HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR; PERAMIVIR; SIALIDASE; ZANAMIVIR;

ANTIVIRAL ACTIVITY; CRYSTAL STRUCTURE; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFICACY; DRUG STRUCTURE; ENZYME INHIBITION; GENE MUTATION; HUMAN; IC 50; IN VITRO STUDY; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS B; MORTALITY; NONHUMAN; REVIEW; SYMPTOMATOLOGY; VIRUS REPLICATION; VIRUS RESISTANCE;

AMINO ACID SUBSTITUTION; ANIMALS; ANTIVIRAL AGENTS; BINDING SITES; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; CYCLOPENTANES; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, MULTIPLE, VIRAL; DRUG RESISTANCE, VIRAL; GUANIDINES; HUMANS; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA, HUMAN; MICE; MOLECULAR STRUCTURE; NEURAMINIDASE; ORTHOMYXOVIRIDAE; OSELTAMIVIR; POINT MUTATION; VIRAL PROTEINS;

EID: 33846886514     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Betts, R.F. Influenza virus. En: Mandell, G.L., Bennett, J.E., Dolin, R. (Eds.). Principles and practice of infectious diseases. Churchill Livingstone, New York 1995; 1546-1567.
2. Murphy, B.R., Webster, R.G. Orthomyxoviruses. En: Fields, B.N., Knipe, D.M., Howlet, P.M. (Eds.). Fields Virology, 4th. Lippincott-Williams & Wilkins Publishers, Philadelphia 2001; 1533-1579.
3. Webster, R.G., Bean, W.J., Gorman, O.T., Chambers, T.M., Kawaoka, Y. Evolution and ecology of influenza A viruses. Microbiol Rev 1992; 56: 152-179.
4. Reina, J. La gripe aviar. Una amenaza constante para el ser humano. Med Clin (Barc) 2004; 122: 339-341.
5. Monto, A.S., Iacuzio, D.A., LaMontagne, J.R. Pandemic influenza. Confronting a reemergent threat. J Infect Dis 1997; 176: 1-3.
6. Hampson, A.W. Surveillance for pandemic influenza. J Infect Dis 1997; 176: S8-13.
7. Palese, P., Zavala, F., Muster, T., Nussenzweig, R.S., García-Sastre, A. Development of novel influenza virus vaccine and vectors. J Infect Dis 1997; 176: S45-49.
8. Monto, A.S. Prospects for pandemic influenza control with currently available vaccines and antivirals. J Infect Dis 1997; 176: 32-37.
9. Lamb, R.A., Krug, R.M. Orthomyxoviridae: The viruses and their replication. En: Knipe, D.M., Howley, P.M. (Eds.). Fields Virology, 4th. Lippincott Williams & Wilkins, Philadelphia 2001; 1487-1532.
10. Burmeister, W.P., Ruigrok, R.W., Cusack, S. The 2.2A resolution crystal structure of influenza B neuraminidase and its complex with sialic acid. EMBO J 1992; 11: 49-56.
11. Varhese, J.N., McKimm-Breschkin, J.L., Caldwell, J.B., Kortt, A.A., Colman, P.M. The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. Proteins 1992; 14: 327-332.
12. Oxford, J. Oseltamivir. Drugs Context 2004; 1: 313-356.
13. Reina, J. Profilaxis y tratamiento de las infecciones respiratorias causadas por los virus influenza A y B. Rev Esp Quimioterap 1999; 12: 23-29.
14. Reina, J. Inhibidores de la neuraminidasa y su potencial utilización en lapandemia de gripe aviar. Med Clin (Barc) 2005; 125: 780-783.
15. Babu, Y.S., Chand, P., Bantia, S. y cols. BCX-1812 (RWJ-270201): Discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. J Med Chem 2000; 43: 3482-3486.
16. Calfee, D.P., Hayden, F.G. New approaches to influenza chemotherapy: Neuraminidase inhibitors. Drugs 1998; 56: 537-553.
17. Kim, C.U., Chen, X., Mendel, D.B. Neuraminidase inhibitors as anti-influenza virus agents. Antiviral Chem Chemother 1999; 10: 141-154.
18. Gubareva, L.V., Kaiser, L., Hayden, F.G. Influenza virus neuraminidase inhibitors. Lancet 2000; 355: 827-835.
19. Smee, D.F., Huffman, J.H., Morrison, A.C., Barnard, D.L., Sidwell, R.W. Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities. Antimicrob Agents Chemother 2001; 45: 743-748.
20. Young, D., Fowler, C., Busk, K. RWJ-270201 (CX-1812): A novel neuraminidase inhibitor for influenza. Phil Trans R Soc Lond Biol Sci 2001; 356: 1905-1913.
21. Sidwell, R.W., Smee, D.F. Peramivir (BCX-1812, RWJ-270201): Potential new therapy for influenza. Expert Opin Investig Drugs 2002; 11: 859-869.
22. Bantia, S., Parker, C.D., Ananth, S.L. y cols. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir. Antimicrob Agents Chemother 2001; 45: 1162-1167.
23. Sidwell, R.W., Smee, D.F., Huffman, J.H. y cols. In vivo influenza virus-inhibitory effects of the cyclopentane neuraminidase inhibitor RWJ-270201. Antimicrob Agents Chemother 2001; 45: 749-757.
24. Roberts, N.A. Treatment of influenza with neuraminidase inhibitors: Virological implications. Phil Trans R Soc Lond Biol Sci 2001; 356: 1895-1897.
25. Smee, D.F., Bailey, K.W., Morrison, A.C., Sidwell, R.W. Combination treatment of influenza A virus infections in cell culture and in mice with the cyclopentane neuraminidase inhibitor RWJ-270201 and ribavirin. Chemotherapy 2002; 48: 88-93.
26. Govorkova, E.A., Leneva, I.A., Goloubeva, O.G., Bush, K., Webster, R.G. Comparison of efficacies of RWJ-70201, zanamivir and oseltamivir against H5N1, H9N2 and other avian influenza viruses. Antimicrob Agents Chemother 2001; 45: 2723-2732.
27. Sweet, C., Jakerman, K.J., Bush, K. y cols. Oral administration of cyclopentane neuraminidase inhibitors protects ferrets against influenza virus infection. Antimicrob Agents Chemother 2002; 46: 996-1004.
28. Drusano, G.L., Preston, S.L., Smee, D., Bush, K., Bailey, K., Sidwell, R.W. Pharmacodynamic evaluation of RWJ-270201, a novel neuraminidase inhibitor, in a lethal murine model of influenza predicts efficacy for once-daily dosing. Antimicrob Agents Chemother 2001; 45: 2115-2118.
29. Iyer, G.R., Liao, S., Massarella, J. Population analysis of the pharmacokinetics and pharmacodynamics of RWJ-270201 (BCX-1812) in treating experimental influenza A and B virus in healthy volunteers. Pharm Sci 2002; 4: E22.
30. Sidwell, R.W., Bailey, K.W., Morrey, J.D., Wing, M.H., Baldwin, T.J., Smee, D.F. Inhibition of influenza virus infections in immunosuppressed mice with orally administered peramivir (BCX-1812). Antiviral Res 2003; 60: 17-25.
31. Bantia, S., Arnold, C.S., Parker, C.D., Upshaw, R., Chand, P. Anti-influenza virus activity of peramivir in mice with single intramuscular injection. Antiviral Res 2006; 69: 39-45.
32. Stilianakis, N.L., Perelson, A.S., Hayden, F.G. Drug resistance and influenza pandemics. Lancet 2002; 359: 1862-1863.
33. McKimm-Breschkin, J., Trivedi, T., Hampson, A. y cols. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob Agents Chemother 2003; 47: 2264-2272.
34. Jackson, H.C., Roberts, N., Wang, Z.M., Belshe, R. Management of influenza: Use of new antivirals and resistance in perspective. Clin Drug Invest 2000; 20: 447-454.
35. McKimm-Breschkin, J.L. Resistance of influenza viruses to neuraminidase inhibitors. Antiviral Res 2000; 47: 1-17.
36. Gubareva, L.V., Webster, R.G., Hayden, F.G. Cross resistance of influenza virus mutants to NA inhibitors: Zanamivir, GS4071 and RWJ-270201. Antiviral Res 2000; 46: A54.
37. Bantia, S., Ananth, S., Horn, L. y cols. Generation and characterization of a mutant of influenza A virus selected with the neuraminidase inhibitor RWJ-270201. Antiviral Res 2000; 46: A60.
38. Gubareva, L.V., Webster, R.G., Hayden, F.G. Comparison of the activities of zanamivir, oseltamivir and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Antimicrob Agents Chemother 2001 ; 45: 3403-3408.
39. Smee, D.F., Sidwell, R.W., Morrison, A.C., Bailey, K.W., Baum, E.Z., Wagaman, P.C. Characterization of an influenza A (H3N2) virus resistant to the cyclopentane neuraminidase inhibitor RWJ-270201. Antiviral Res 2001; 52: 251-259.
40. Baum, E.Z., Wagaman, P.C., Ly, L. y cols. A point mutation on influenza B neuraminidase confers resistance to peramivir and loss of slow binding. Antiviral Res 2003; 59: 13-22.
41. Mishin, V.P., Hayden, F.G., Gubareva, L.V. Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob Agents Chemother 2005; 49: 4515-4520.
42. Johnson, R.W. Pharmaceutical Research Institute, Raritan, New Jersey, USA 2000.